Brief: Arch Biopartners Enters Into Worldwide License Agreement With Telara Pharma To Re-Purpose Cilastatin For Treatment & Prevention Of Acute Kidney Injury
15/04/2021 12:34
April 15 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ENTERS INTO WORLDWIDE LICENSE AGREEMENT
WITH
TELARA PHARMA TO RE-PURPOSE CILASTATIN FOR TREATMENT &
PREVENTION OF ACUTE KIDNEY INJURY
* ARCH BIOPARTNERS INC - WITH LICENSE, ARCH SECURES
COMMERCIAL
RIGHTS TO PATENTS AROUND USE OF CILASTATIN THAT IT DOES NOT
ALREADY OWN
* ARCH BIOPARTNERS INC - PATENTS HELD BY ARCH AND TELARA ARE
NOW
UNIFIED INTO ONE CLINICAL DEVELOPMENT PROGRAM TO BE LED BY ARCH
* ARCH BIOPARTNERS INC - NEW LICENSE FURTHER ADDS TO ARCH
PIPELINE
OF DPEP-1 TARGETING AGENTS
* ARCH BIOPARTNERS INC - TELARA WILL PROVIDE PHASE I SAFETY
DATA
& NEWLY ESTABLISHED CILASTATIN DRUG MANUFACTURING PROGRAM
Source text for Eikon: ID:nGNX5hQQWF
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide